We’re keeping our fingers crossed for a new treatment for X-linked hypophosphatemia (XLH) that is being considered by the Pharmaceutical Benefits Advisory Committee (PBAC) in March 2022.
The PBAC has opened its consumer comments portal so we’re encouraging all members of our XLH community to share their story.
Fingers crossed!